Emerging Lessons From COVID-19 for the US Clinical Research Enterprise | Research, Methods, Statistics | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
Views 17,629
Citations 0
Editorial
February 26, 2021

Emerging Lessons From COVID-19 for the US Clinical Research Enterprise

Author Affiliations
  • 1UPMC and the University of Pittsburgh Schools of the Health Sciences, Pittsburgh, Pennsylvania
  • 2Senior Editor, JAMA
  • 3Division of Anaesthetics, Pain Medicine and Intensive, Imperial College London, London, England
  • 4Intensive Care Unit, St Mary’s Hospital, London, England
  • 5Editor in Chief, JAMA
JAMA. 2021;325(12):1159-1161. doi:10.1001/jama.2021.3284

In this issue of JAMA, Janiaud et al1 present a meta-analysis of randomized clinical trials (RCTs) of convalescent plasma for the treatment of patients with COVID-19. Based on an analysis of 1060 patients from 4 RCTs published in peer-reviewed journals and 10 722 patients from 6 RCTs (5 published as preprints and 1 as a press release), the authors found that treatment with convalescent plasma vs placebo or standard of care was not associated with a significant decrease in all-cause mortality (risk ratio, 0.93 [95% CI, 0.63-1.38] for the 4 peer-reviewed RCTs; risk ratio, 1.02 [95% CI, 0.92-1.12] for all 10 RCTs) or with benefit for other clinical outcomes, including length of hospital stay, mechanical ventilation use, and clinical improvement or deterioration.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×